Previous 10 | Next 10 |
2023-10-26 18:02:05 ET Gainers: CVRx ( VRX ) +29% . Eargo ( EAR ) +28% . DexCom ( DXCM ) +15% . Masimo Corporation ( MASI ) +13% . Groupon ( GRPN ) +9% . Losers: Enphase Energy ( ENPH ) -17% . PTC Therapeutics...
2023-10-26 16:28:40 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript PTC Therapeutics Q3 2023 Earnings Preview Royalty Pharma to buy up to $1.5B of PTC Therapeu...
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PR Newswire – Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position fo...
PTC Therapeutics Inc. (PTCT) is expected to report $-0.85 for Q3 2023
2023-10-19 19:02:30 ET A new royalty deal was the fuel that powered biotech PTC Therapeutics (NASDAQ: PTCT) stock to a 15% gain on Thursday. That arrangement, which covers PTC's spinal muscular atrophy (SMA) treatment Evrysdi, features a hefty upfront payment that could also bring i...
2023-10-19 08:31:42 ET More on PTC, Roche, etc. Recursion Pharmaceuticals: Wet Lab Meets Silicon, A Tale Of Two Bottom Lines Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-line Q3 sales Roche in pact wit...
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PR Newswire - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing pro...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- ...
2023-10-06 10:52:41 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript PTC Technologies announces workforce reduction impacting 25% of the company Citi lowers PTC...
2023-09-28 16:57:30 ET More on PTC Therapeutics PTC Therapeutics: Struggling Still But Potential Remains PTC Therapeutics, Inc. (PTCT) Q2 2023 Earnings Call Transcript Citi lowers PTC Therapeutics to neutral amid uncertainty for DMD drug Larimar, Design highe...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Validation of Sepiapterin European MAA PR Newswire - Review of European marketing application for PKU now initiated - WARREN, N.J. , May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sep...
2024-05-20 20:15:01 ET Citigroup analyst issues SELL recommendation for PTCT on May 20, 2024 07:00PM ET. The previous analyst recommendation was Sell. PTCT was trading at $40.12 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering...